title: Home self-administration of omalizumab for chronic spontaneous urticaria.
authors.affiliation: Department of Clinical Immunology and Allergy, St James's University Hospital, Beckett Street, Leeds, U.K.
authors.forename: S
authors.initials: S
authors.lastname: Denman
authors.affiliation: Department of Clinical Immunology and Allergy, St James's University Hospital, Beckett Street, Leeds, U.K.
authors.forename: K
authors.initials: K
authors.lastname: Ford
authors.affiliation: Department of Clinical Immunology and Allergy, St James's University Hospital, Beckett Street, Leeds, U.K.
authors.forename: J
authors.initials: J
authors.lastname: Toolan
authors.affiliation: Department of Clinical Immunology and Allergy, St James's University Hospital, Beckett Street, Leeds, U.K.
authors.forename: A
authors.initials: A
authors.lastname: Mistry
authors.affiliation: Department of Clinical Immunology and Allergy, St James's University Hospital, Beckett Street, Leeds, U.K.
authors.forename: C
authors.initials: C
authors.lastname: Corps
authors.affiliation: Department of Clinical Immunology and Allergy, St James's University Hospital, Beckett Street, Leeds, U.K.
authors.forename: P
authors.initials: P
authors.lastname: Wood
authors.affiliation: Department of Clinical Immunology and Allergy, St James's University Hospital, Beckett Street, Leeds, U.K.|National Institute for Health Research-Leeds Musculoskeletal Biomedical Research Unit (NIHR-LMBRU) and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Wellcome Trust Brenner Building, St James's University Hospital, Beckett Street, Leeds, U.K.
authors.forename: S
authors.initials: S
authors.lastname: Savic
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D003362:Cost-Benefit Analysis; D006801:Humans; D000069444:Omalizumab / Q000627:therapeutic use*; D012646:Self Administration; D016896:Treatment Outcome; D014581:Urticaria / Q000188:drug therapy*
chemical_list: D018926:Anti-Allergic Agents; D000069444:Omalizumab